drugset / Trial / NCT00019006

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

NCT00019006

Treatment

Summary

RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.

Timeline

Start
1995-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ras peptide cancer vaccine Vaccine Subcutaneous
Background Detox-B Unknown Subcutaneous